Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61438
http://purl.obolibrary.org/obo/NCIT_C61438
|
|---|---|
| Preferred Name | Alacizumab Pegol |
| Definitions |
A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs. |
|---|---|
| prefLabel | Alacizumab Pegol
|
| label | Alacizumab Pegol
|
| PDQ_Closed_Trial_Search_ID | 472077
|
| code | C61438
|
| prefixIRI | NCIT:C61438
|
| in_subset | |
| Preferred_Name | Alacizumab Pegol
|
| FDA_UNII_Code | ZL9780F883
|
| Contributing_Source | FDA
|
| Maps_To | Alacizumab Pegol
|
| CAS_Registry | 934216-54-3
|
| NCI_Drug_Dictionary_ID | 472077
|
| Legacy Concept Name | Pegylated_Anti-GRF_Antibody_Fragment
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 472077
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1831765
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |